Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials
-
Published:2023-10
Issue:
Volume:230
Page:27-32
-
ISSN:0049-3848
-
Container-title:Thrombosis Research
-
language:en
-
Short-container-title:Thrombosis Research
Author:
Barco StefanoORCID, Virdone Saverio, Götschi Andrea, Ageno Walter, Arcelus Juan I., Bingisser Roland, Colucci Giuseppe, Cools Frank, Duerschmied Daniel, Gibbs Harry, Fumagalli Riccardo M., Gerber Bernhard, Haas Sylvia, Himmelreich Jelle C.L., Hobbs Richard, Hobohm Lukas, Jacobson Barry, Kayani Gloria, Lopes Renato D., MacCallum Peter, Micieli Evy, Righini Marc, Robert-Ebadi Helia, Rocha Ana Thereza, Rosemann Thomas, Sawhney Jitendra, Schellong Sebastian, Sebastian Tim, Spirk David, Stortecky Stefan, Turpie Alexander G.G., Voci Davide, Kucher Nils, Pieper Karen, Held Ulrike, Kakkar Ajay K.
Reference21 articles.
1. WHO Coronavirus (COVID-19) Dashboard;Organization, W.H,2022 2. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy;Lodigiani;Thromb. Res.,2020 3. Randomized trials of therapeutic heparin for COVID-19: a meta-analysis;Sholzberg;Res. Pract. Thromb. Haemost.,2021 4. Prevention of venous thromboembolism in surgical patients;Agnelli;Circulation,2004 5. The anti-inflammatory effects of heparin and related compounds;Young;Thromb. Res.,2008
|
|